Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials
Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Learn More
Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Press Release Archive
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) AmyloidosisDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) AmyloidosisAccelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder.
-
Johnson & Johnson Statement on Political ContributionsJohnson & Johnson Statement on Political Contributions
-
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of MedicineJohnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
-
Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung CancerJanssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung CancerUpdated amivantamab data from the Phase 1 CHRYSALIS study and new data characterizing the high unmet need among patients with non-small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations to be presented
-
Statement by Alex Gorsky, Johnson & Johnson Chairman and CEOStatement by Alex Gorsky, Johnson & Johnson Chairman and CEO
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2021Johnson & Johnson Announces Quarterly Dividend for First Quarter 2021
-
Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple MyelomaJanssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
-
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter ResultsJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
-
Johnson & Johnson to Participate in the 39th Annual J.P. Morgan Healthcare ConferenceJohnson & Johnson to Participate in the 39th Annual J.P. Morgan Healthcare Conference
-
New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic LeukemiaNew Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic LeukemiaIMBRUVICA® pooled clinical trial analyses presented at ASH demonstrate sustained efficacy and safety in patients with historically poor outcomesData from real-world evidence studies featured as oral presentations highlight the benefit of IMBRUVICA®-based therapies in the first-line setting